Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 4, Pages 1153
Publisher
MDPI AG
Online
2018-04-12
DOI
10.3390/ijms19041153
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
- (2018) Dilan Athauda et al. NEUROPHARMACOLOGY
- Effect of D-Ala 2 GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice
- (2017) Mahip K. Verma et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease
- (2017) Ziyue Yuan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
- (2017) Yanwei Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury
- (2017) Ian A. Tamargo et al. EXPERIMENTAL NEUROLOGY
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Predictors of anxiety in early-stage Parkinson's disease – Results from the first two years of a prospective cohort study
- (2017) Sonja Rutten et al. PARKINSONISM & RELATED DISORDERS
- Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
- (2017) Tsuyoshi Yanagimachi et al. Molecular Metabolism
- Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson’s disease
- (2017) Caroline J. Zeiss et al. PLoS One
- A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF
- (2016) Chenhui Ji et al. BRAIN RESEARCH
- Glucose-Dependent Insulinotropic Polypeptide Ameliorates Mild Traumatic Brain Injury-Induced Cognitive and Sensorimotor Deficits and Neuroinflammation in Rats
- (2016) Yu-Wen Yu et al. JOURNAL OF NEUROTRAUMA
- Prevalence of anxiety in Parkinson's disease: A systematic review and meta-analysis
- (2016) Martijn P. G. Broen et al. MOVEMENT DISORDERS
- Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
- (2016) Yanwei Li et al. NEUROPHARMACOLOGY
- A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat
- (2016) Ling Han et al. NEUROREPORT
- Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases
- (2016) Yanwei Li et al. REVIEWS IN THE NEUROSCIENCES
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease
- (2014) Christian Hölscher Alzheimers & Dementia
- Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury
- (2014) Nigel H. Greig et al. Alzheimers & Dementia
- Comment: Why do nondopaminergic features in Parkinson disease matter?
- (2014) W. Maetzler NEUROLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Gut hormones as therapeutic agents in treatment of diabetes and obesity
- (2013) Tricia Tan et al. CURRENT OPINION IN PHARMACOLOGY
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies
- (2013) C. G. Goetz Cold Spring Harbor Perspectives in Medicine
- Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
- (2012) Lital Rachmany et al. AGE
- Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
- (2012) Isidro Salcedo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice
- (2012) David Tweedie et al. EXPERIMENTAL NEUROLOGY
- Time-course gait analysis of hemiparkinsonian rats following 6-hydroxydopamine lesion
- (2011) Tsung-Hsun Hsieh et al. BEHAVIOURAL BRAIN RESEARCH
- Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases
- (2010) Cláudia P. Figueiredo et al. BEHAVIOURAL PHARMACOLOGY
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
- On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
- (2009) Meena Asmar et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes
- (2008) Victor A. Gault et al. BIOCHEMICAL PHARMACOLOGY
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Protease-Resistant Glucose-Dependent Insulinotropic Polypeptide Agonists Facilitate Hippocampal LTP and Reverse the Impairment of LTP Induced by Beta-Amyloid
- (2008) Victor A. Gault et al. JOURNAL OF NEUROPHYSIOLOGY
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started